Avidity Partners Management’s Biogen BIIB Stock Holding History

Avidity Partners Management’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-115,400	Closed	-$29.7M	–	77
2023 Q3	$29.7M	Sell	115,400 -58,600	-34%	-$15.7M	1.19%	39
2023 Q2	$49.6M	Buy	174,000 +45,200	+35%	+$13.5M	1.73%	20
2023 Q1	$35.8M	Buy	+128,800	New	+$35.6M	1.19%	34
2022 Q4	–	Sell	-600,000	Closed	-$160M	–	90
2022 Q3	$160M	Buy	600,000 +159,434	+36%	+$33.9M	3.26%	7
2022 Q2	$89.8M	Buy	440,566 +75,566	+21%	+$15.4M	2.06%	22
2022 Q1	$76.9M	Buy	+365,000	New	+$79.4M	1.6%	23
2021 Q3	–	Sell	-183,900	Closed	-$63.7M	–	108
2021 Q2	$63.7M	Buy	+183,900	New	+$55.7M	1.72%	19
2020 Q4	–	Sell	-315,100	Closed	-$81.3M	–	103
2020 Q3	$89.4M	Buy	+315,100	New	+$87.9M	4.15%	6
2020 Q2	–	Sell	-62,000	Closed	-$19.6M	–	60
2020 Q1	$19.6M	Buy	+62,000	New	+$18.8M	2.71%	11

Other funds holding BIIB

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

Avidity Partners Management's BIIB Position: Q4 2023 in Review

Avidity Partners Management sold out of Biogen (BIIB) in Q4 2023, closing a stake of 115,400 shares — an estimated $29.7M sold.

Avidity Partners Management first reported a position in BIIB in Q1 2020 and held it in 9 quarters. The position peaked at $160M in Q3 2022. 1,003 funds tracked by Wall St. Rank hold BIIB as of Q4 2023.

Avidity Partners Management reported no remaining Biogen position as of Q4 2023 after selling out during the quarter.
Avidity Partners Management sold 115,400 Biogen shares in Q4 2023, an estimated $29.7M.
Avidity Partners Management first reported a position in Biogen in Q1 2020 and held it in 9 quarters.
Avidity Partners Management's Biogen position peaked at $160M in Q3 2022.
1,003 funds tracked by Wall St. Rank held Biogen as of Q4 2023.

Based on Avidity Partners Management's 13F filing for Q4 2023, filed 14 Feb 2024.